Normosang (Human Hemin)

• Normosang provides heme replacement therapy for acute porphyria disorders, helping to control neurotoxic precursor buildup.
• Acute intermittent porphyria: reduces accumulation of neurotoxic porphyrin precursors and alleviates acute attacks.
• Acute hepatic porphyria: supplies exogenous heme to suppress aminolevulinic acid synthase activity during crises.
• Porphyria‑related neurovisceral crises: restores heme levels to improve neurological symptoms.
• Variegate porphyria attacks: provides heme to reduce symptom severity.

• Human Hemin acts as an exogenous source of heme that feeds back to inhibit the first enzyme of the porphyrin synthesis pathway, aminolevulinic acid synthase (ALAS). By down‑regulating ALAS activity, the drug decreases the production of aminolevulinic acid and porphobilinogen, limiting the buildup of neurotoxic intermediates that trigger acute porphyria attacks. The restored heme pool also supports normal cytochrome function in hepatic cells, contributing to metabolic balance.

Human Hemin may be associated with several adverse reactions, ranging from mild infusion‑related events to rare serious conditions.

Common Side Effects

• Infusion site pain or phlebitis
• Nausea or vomiting
• Headache
• Fever or chills
• Elevated liver enzymes
• Mild hypotension

Serious or Rare Side Effects

• Anaphylactic or severe allergic reaction
• Hemolysis, especially in patients with G6PD deficiency
• Acute renal failure
• Severe hypotension or shock

• When using Normosang, clinicians should observe specific safety measures to minimize risks.
• Monitor for hemolysis: assess hemoglobin and bilirubin levels, especially in G6PD‑deficient patients.
• Check liver function: perform baseline and periodic liver enzyme tests.
• Avoid rapid infusion: administer over the recommended period to reduce cardiovascular reactions.
• Use under specialist supervision: treatment should be managed by physicians experienced in porphyria care.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Human Hemin can interact with other medicines, influencing porphyria management or altering drug effects.

Major Interactions (Avoid)

• Concomitant use of porphyrinogenic drugs (e.g., barbiturates, sulfonamides) may exacerbate porphyria attacks.
• Co‑administration with phenobarbital can increase neurotoxic precursor accumulation.

Moderate Interactions (Monitor Closely)

• Anticoagulants such as warfarin may have altered INR values; monitor coagulation.
• Iron supplements may affect iron homeostasis; observe ferritin levels.
• Live vaccines should be used with caution as immune response may be affected.